Immunologic effect of zinc supplementation in HIV infected children receiving highly active antiretroviral therapy: A randomized, double blind placebo controlled trial.
Not Applicable
- Conditions
- Health Condition 1: null- HIV
- Registration Number
- CTRI/2009/091/000971
- Lead Sponsor
- Indian Council of Medical Research New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
HIV infected children older than 6 months in whom initiation of antiretroviral therapy is indicated as per current guidelines (NACO).
Exclusion Criteria
1. Children receiving zinc supplementation at time of screening for enrollment.
2. Children with clinical evidence of zinc deficiency.
3. Sick children with concurrent other infections, including pneumonia, diarrhea, TB.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CD4% valueTimepoint: 12 weeks and 24 weeks
- Secondary Outcome Measures
Name Time Method Viral loadTimepoint: 12 weeks and 24 weeks